US Inhaled Insulin Therapeutic Choice Questionnaire Study
Public ClinicalTrials.gov record NCT00139763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A US Randomized Questionnaire-Based Trial Assessing The Impact Of The Availability Of Inhaled Insulin On Therapeutic Choice In Patients With Suboptimally Controlled Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments. This study will also ask if patients with uncontrolled type 2 diabetes currently managed on diabetes pills + once daily insulin will choose as the next treatment choice to take insulin multiple times a day if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
Study identification
- NCT ID
- NCT00139763
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 740 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2005
- Primary completion
- Not listed
- Completion
- Feb 28, 2006
- Last update posted
- Mar 18, 2007
2005 – 2006
United States locations
- U.S. sites
- 42
- U.S. states
- 25
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Chandler | Arizona | 85224 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85201 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85006-2850 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85051 | — |
| Pfizer Investigational Site | Tempe | Arizona | 85282 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | San Diego | California | 92120 | — |
| Pfizer Investigational Site | Colorado Springs | Colorado | 80904 | — |
| Pfizer Investigational Site | Newark | Delaware | 19713 | — |
| Pfizer Investigational Site | Wilmington | Delaware | 19805 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010-2934 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32205 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | — |
| Pfizer Investigational Site | Hayden | Idaho | 83835 | — |
| Pfizer Investigational Site | Nampa | Idaho | 83714 | — |
| Pfizer Investigational Site | Gurnee | Illinois | 60031 | — |
| Pfizer Investigational Site | Elkton | Maryland | 21921 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48235 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55416 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | — |
| Pfizer Investigational Site | Margate City | New Jersey | 08402-2218 | — |
| Pfizer Investigational Site | Santa Fe | New Mexico | 87505 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | Morehead City | North Carolina | 28557 | — |
| Pfizer Investigational Site | Salisbury | North Carolina | 28144 | — |
| Pfizer Investigational Site | Statesville | North Carolina | 28625 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45236 | — |
| Pfizer Investigational Site | Portland | Oregon | 97219 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239 | — |
| Pfizer Investigational Site | Orangeburg | South Carolina | 29118 | — |
| Pfizer Investigational Site | Simpsonville | South Carolina | 29681 | — |
| Pfizer Investigational Site | Arlington | Texas | 76014-2010 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Madisonville | Texas | 77864 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Bennington | Vermont | 05201-5018 | — |
| Pfizer Investigational Site | Virginia Beach | Virginia | 23462 | — |
| Pfizer Investigational Site | Spokane | Washington | 99207 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Diabetes Mellitus, Type 2 trials
Other public records listing Diabetes Mellitus, Type 2. Sorted by last update posted; newest first. Not a recommendation.
- NCT06920355: Community Pharmacy Produce Prescriptions Active, not recruiting
- NCT07784270: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Not yet recruiting
- NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
- NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting
- NCT07590193: A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus Recruiting
- NCT07242469: A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00139763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2007 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00139763 live on ClinicalTrials.gov.